Clinical Trial Update: Node-Sparing Short-Course Radiation Combined With Capecitabine and PD-1/CTLA-4 for MSS Early Rectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial assessing node-sparing short-course radiation with capecitabine and PD-1/CTLA-4 inhibitors for microsatellite-stable early rectal cancer is curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• Capecitabine (Xeloda) (Capecitabine)

Snippet

Sponsor: Sir Run Run Shaw Hospital | Conditions: Rectal Cancer | Phase 2 | Status: RECRUITING